China Experts Believe Tainted Heparin Not Liable For Adverse Effects
This article was originally published in PharmAsia News
Seven Chinese experts appointed by China's Ministry of Health and State FDA think that the adverse heparin incidents in the U.S and other countries cannot be conclusively attributed to impurities in heparin raw materials. The group met up with 11 international peers from the U.S., Australia, Denmark, Germany, France, Korea, Netherlands, Canada, Japan, Italy and Singapore to discuss heparin quality standards, testing methods, clinical side effects, source tracing and supply. Based on the following evidence, the Chinese experts surmised that the tainted heparin cannot be conclusively linked to the side effects. Injections produced by American firms Covidien and B.Braun, which used tainted heparin raw materials from China did not give rise to any bad reaction; on the other hand, some batches of Baxter's injections without the ingredients had caused serious side effects. (Click here for more - Chinese Language)
You may also be interested in...
Veklury is now the first US FDA-approved treatment for COVID-19, but its limited benefits means its lifespan as a blockbuster could be short.
As negotiations between the UK and EU enter a crucial phase, the UK life sciences industry has called for more clarity and guidance on what companies can expect to face at the end of the Brexit transition period.
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.